NCT05266924进行中（未招募）3 期
A Randomized, Parallel-group, Multi-Center, Assessor-blind Phase 3 Study to Compare the Efficacy, Safety and Ease of Use of Two Follicle Stimulating Hormone -Human Recombinant (r-hFSH) 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen (Foligraf®- Manufactured by BSV and Gonal-f® Manufactured by Merck Serono) in Subjects Undergoing Controlled Ovarian Stimulation for Assisted Reproductive Technology
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Number of oocytes retrieved
研究概览
简要总结
This is a randomized multi-centre, assessor-blind, parallel-group study to be conducted in 250 women in the age group of 20 to 39 years (both inclusive), who are indicated to undergo COS as part of assisted reproductive technology (ART). The participant will receive r-hFSH, fixed-dose for 5 days, and day 6 onwards the dose may be adjusted for a single cycle of COS followed by ART procedures, and post-ART follow-up for ongoing pregnancy.
The primary and secondary outcomes will be captured on days as per protocol. Adverse events will be noted for safety evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
盲法说明
The assessor including the investigator, outcoume assessor (sonography, embyrologist) shall be blinded.
入排标准
- 年龄范围
- 20 Years 至 39 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subject has indication ART using COS.
- •Subject has regular menstrual cycle of 21-35 days.
- •Subject has one of the following:
- •FSH level <10 IU/L and Estradiol levl <80 pg/mL at day 2 or 3
- •Anti-mullerian hormone (AMH) level between 1 to 3.5 ng/mL during the menstrual cycle
- •Subject has an antral follicle count (AFC) of 10- 25, follicle ≤10 mm in diameter before ovarian stimulation
- •Subject has a BMI ≥18 and <30 kg/m2
- •Subject has results of clinical laboratory tests within normal reference range
- •Subject and her partner are willing to provide written informed consent and comply
- •Exclusion Criteria Details Subject has history of >2 failed ART cycles
- •Subject with history of any endocrine abnormality, with documented hormone levels outside the reference range, which are clinically relevant, at screening
- •Subject with a history of ovarian hyper-response (i.e., previous COS cycle with >25 follicles of ≥11 mm in diameter on USG) or OHSS
- •Subject with documented polycystic ovarian syndrome (PCOS) at the time of screening
- •Subject with only one ovary or ovarian abnormality (including endometrioma >10 mm; visible on USG), at screening
- •Subject with documented severe endometriosis (American Society of Reproductive Medicine stage 3 or stage 4) or hydrosalpinx, at screening
- •Subject with submucosal fibroids ≥5 cm or any other clinically relevant pathology, which could impair embryo implantation or pregnancy continuation, at screening
- •Subject with a history of extrauterine pregnancy within 3 months of screening
- •Subject with history of poor response to gonadotropin treatment (retrieval of <4 oocytes) in the previous ART cycle
- •Subject with history of ≥3 miscarriages, at any time prior to screening
- •Subject who has tested positive for Human Immunodeficiency Virus, Hepatitis B or Hepatitis C at screening
- •Subject known to be allergic, hypersensitive, or intolerant to any of the preparations of r hFSH or its excipients, that will be used in the study
- •Subject with contraindications to the use of gonadotropins (e.g., tumours, undiagnosed vaginal bleeding, or ovarian cysts) or gonadotropin-releasing hormone (GnRH) antagonists
- •Subject with a history of epilepsy, thrombophilia, cardiovascular, gastrointestinal, hepatic, renal, pulmonary, auto-immune disease, or any active infection, requiring treatment which at the investigator's discretion might interfere with the study
- •Subject with history of malignancy
- •Subject who smokes or has stopped smoking within the last 3 months prior to screening
- •Subject with history of alcohol or drug abuse within 12 months prior to screening
- •Subject who has received any treatment listed below within 5 half-lives prior to screening:
- •Any agent(s) known to affect ovulation (e.g., neuroleptics);
- •Drugs known or suspected to be teratogenic in nature.
排除标准
- 未提供
研究组 & 干预措施
Test group
Experimental
Foligraf 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen Follicle Stimulating Hormone (Human Recombinant) manufactured by Bharat Serums and Vaccines Ltd
干预措施: Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen (Drug)
Reference group
Active Comparator
Gonal-f Recombinant Human Follicle Stimulating Hormone
干预措施: Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen (Drug)
结局指标
主要结局
Number of oocytes retrieved
时间窗: Oocyte pick up - up to ~ 34 to 36 hours after human chorionic gonadotropin (hCG) administration
Number of oocytes retrieved
次要结局
- Ongoing Pregnancy rate(11±1 weeks after ET)
- Cycle cancellation rate(at Stimulation phase up to 20 days, oocyte pick up up to ~ 34 to 36 hours after hCG administration, ET anytime up to 8 weeks)
- Clinical pregnancy rate(4 weeks after embryo transfer (ET))
- Total Doseof r-hFSH(at end of stimulation up to 20 days)
- Number of Days of r-hFSH stimulation(at end of stimulation up to 20 days)
- Number of subject Change in Dosage(post Day 6 till end of stimulation up to 20 days)
- Hormonal Investigation(Day 6)
- Follicle size on Day 6(Day 6)
- Number of good quality embryos(ET day (up to 8 weeks))
- Follicle size at HCG administration(Day of hCG administration anytime upto 3 weeks)
- Endometrium thickness(day 6)
- Endometrium at HCG administration(day of hCG injection (anytime upto 3 weeks))
- Number of Matured oocytes(Oocyte pick up ~ 34 to 36 hours after hCG administration)
- Number of Adverse events(Baseline, 1st day of stimulation, day 6 , end of stimulation up to 20 days, hCG administration, oocyte pick up ~ 34 to 36 hours after hCG administration, ET up to 8 weeks, clinical pregnancy (after 4 weeks of ET), ~12 weeks after ET)
- Specific adverse events(Day 1 of Stimulation till ~12 weeks after ET)
- Exploratory(End of stimulation up to 20 days)
- Evaluation of immunogenicity (antibody) of r-hFSH(Baseline, 4 weeks and 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The USGI Medical ESSENTIAL Study for Weight LossObesityNCT01958385USGI Medical377
已完成
3 期
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisNCT05335356Biocon Biologics UK Ltd384
已完成
3 期
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe AsthmaAsthmaNCT02814643AstraZeneca103
已完成
3 期
Quetiapine Fumarate Bipolar Maintenance MonotherapyBipolar DisorderNCT00314184AstraZeneca1,255
已完成
3 期
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelPulmonary Disease, Chronic ObstructiveNCT04133909GlaxoSmithKline806